The global HIV drugs market is projected to experience significant growth, with a CAGR of 5.46% over the forecast period of 2023-2027. This growth is primarily driven by the increasing prevalence of HIV infections and the demand for effective treatment options. The high-risk populations such as men who have sex with men, intravenous drug users, and sex workers are also contributing to the demand for HIV drugs. The market also benefits from various outlets such as hospital pharmacies, drug stores, retail pharmacies, and online pharmacies offering these medications. New product launches, such as Juluca, continue to enter the market, providing innovative treatment options. Additionally, the import and export of HIV drugs plays a crucial role in the healthcare products industry. With increased funding and resources from governments and organizations, the production and distribution of generic HIV drugs are improving. These factors collectively contribute to the growth of the HIV drugs market.